AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06351397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mixed Reality (MR)
Description: Mixed Reality simulation of medical crisis scenarios.~MR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
Study NCT06548594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Neurostimulation
Description: Transcutaneous Auricular Neurostimulation (tAN) is a wearable, electrical stimulation device that delivers electricity to specific parts of the human ear.
Study NCT05611853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN301
Description: BN301 will be administered intravenously on Day 1 of every 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first. Since this is the first time BN301 will be used in Chinese patients, it is planned to enroll 1 subject at the first dose level of 3.5 mg/kg.
Study NCT05468515 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: pulse oxygen saturation
Description: preductal oxygen saturation
Study NCT06434363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given by vein (IV)
Study NCT06434363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by vein (IV)
Study NCT06434363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by vein (IV)
Study NCT05539196 — intervention group
Intervention type: DEVICE
Intervention: Exablate Pallidotomy, Unilateral
Description: Unilateral pallidotomy using focused ultrasound for the treatment of Parkinson's Disease with medication-refractory moderate to severe motor complications.
Study NCT05276843 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Qigong exercise program
Description: Qigong is a low-impact, weight-bearing exercise characterized by gentle movements designed to dissipate force throughout the body while the subject changes poses, with well-coordinated sequences of both isometric and isotonic segmental movements in the trunk and 4 extremities.
Study NCT06384378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-ER176
Description: ER176 is a PET tracer that binds to the 18 kDa translocator protein (TSPO), which is expressed by activated microglia and astrocytes and is therefore an index of brain inflammation.
Study NCT06384378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 11C-ER176
Description: ER176 is a PET tracer that binds to the 18 kDa translocator protein (TSPO), which is expressed by activated microglia and astrocytes and is therefore an index of brain inflammation.
Study NCT04767360 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bioness-300
Description: Therapeutic treatment of foot drop with the electrical stimulation device Bioness L300.
Study NCT05064644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Product that contains plant stanol ester
Description: Product with active ingredient
Study NCT05064644 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo product
Description: Product without active ingredient
Study NCT06241729 — intervention group
Intervention type: OTHER
Intervention: Algorithms to predict the probability of a primary refractory state
Description: Follow-up of a cohort of patients with diffuse large-cell B lymphoma from 2024 using algorithms to predict the probability of a primary refractory state
Study NCT04981353 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral erector spinae plane block at T11
Description: A real-time high-frequency linear ultrasound will be used to do the thoracic (ESP) at the level of T11 by visualizing the transverse process of T11 thoracic vertebrae and erector spinae muscle and injecting a 20 ml of bupivacaine 0.25% bilaterally using an in-plane technique, a 20-gauge, 70-mm needle (Tuoren, Henan, China) will be advanced into the plane below (ESM) after injecting lidocaine 1% 2ml at the site of injection, Needle will be advanced with a cranial to caudal directio
Study NCT06413745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811
Study NCT05626218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stress ball
Description: The woman is usually laid in the last side position during the procedure. A stress ball will be given to the right hand of the participants during the NST procedure (average 15-20 minutes). This stress ball will be squeezed for 2-3 seconds, and then the hand and arm will be told to relax. This process will be repeated throughout the NST. Hospital protocol will also be applied to these participants.
Study NCT05501067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tai chi exercise
Description: specific tai chi exercise
Study NCT05501067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no intervention
Description: no intervention
Study NCT03271749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROSM guidelines for preoperative, anesthesia and postoperative care for lung resections
Description: The PROSM guidelines is described previously in study description
Study NCT05147298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eHealth phone program
Description: The automated eHealth phone program uses text to speech technology to deliver educational content to increase awareness, confidence, and motivation for physical activity.
Study NCT05147298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environment program
Description: The environment surrounding the PHDs will be changed to make it more amenable to walking by creating walking trails and walking maps and using Healthy Living Advocates (HLA)-led walking groups within the community. Also advocating for changes to the built environment.
Study NCT01692145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCT-0809
Study NCT01692145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05744102 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI Image
Description: MRI sequences
Study NCT06385847 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Zoladex
Description: Patients received 3.6 mg subcutaneous Zoladex
Study NCT06385847 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LY01005
Description: Patients received 3.6 mg intramuscular LY01005
Study NCT06469567 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Patient Counselling
Description: Doctor's counselling using Culturally-responsive pamphlet
Study NCT06469567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Counselling
Description: Doctor's counselling using Culturally-responsive pamphlet
Study NCT06311747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oculo-motor exercises
Description: Oculo-motor exercises will be applied as an intervention. As oculo-motor exercises, 3 different exercises will be applied: stepping exercise with eye movements and head rotation (The eyes are fixed on the thumb and the head rotates right and left and walks 10 steps forward and 10 steps back.), accommodation (First eyes fixed on the near target, then fixed on a target approximately 20-30 m away.) and pen tracking with 5 different movements (Horizontal, vertical, diagonal, circular, infinite eight).
Study NCT04488861 — intervention group
Intervention type: OTHER
Intervention: Non-interventional cohort study
Description: Non-interventional cohort study
Study NCT05557071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health Behaviour Change Platform
Description: Participants will gain access to 6 weekly lessons.~A series of 6 weekly educational modules including information on psychosocial determinants of physical activity engagement, adherence and maintenance, as well as corresponding behaviour change techniques and a number of other tools and strategies, such as reflection activities, quizzes, and worksheets. Mini podcasts are available to supplement the concepts introduced in the modules. The content is tailored for early career professionals. There will be an emphasis on tactics (e.g., mindfulness, acceptance, emotion regulation) to assist with overcoming incidental affect.
Study NCT04920747 — intervention group
Intervention type: DRUG
Intervention: Taxane
Description: docetaxel or paclitaxel
Study NCT05455372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI quadruple therapy
Description: PPI quadruple therapy refers to ilaprazole 5mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid.
Study NCT05146206 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: In this observational study, participants initated on RYALTRIS/DYMISTA nasal spray will complete a cross-sectional online survey that includes a Best-Worst Scaling task to capture their satisfaction and importance of various treatment attributes.
Study NCT05501782 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: A questionnaire consisting of seven parts was applied to the participants. In the first part, 20; demographic data and general health status of the participants; There were 11 questions including nutritional habits and anthropometric measurements (body weight and height). The other parts of the questionnaire were the Intuitive Eating Scale (IES-2), Power of Food Scale (PFS-Tr), Food Craving Questionnaire (FCQ-T), the Pittsburg Sleep Quality Scale (PUKI), Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) and Palatable Eating Motive Scale (PEMS), respectively contains. Consent from the participants was also obtained with the questionnaire form.
Study NCT05987098 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BBPA PET examination
Description: A single dose of 0.10 mCi/kg BBPA will be intravenously injected and PET examination will carry out 30 minutes later.
Study NCT06478134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimix tear substitutes
Description: Patients were instructed to instill 1 drop of TriMix tear substitute into each eye 3 times per day for 6 months.
Study NCT06478134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid tear substitute
Description: Patients were instructed to instill 1 drop of 0.15% HA tear substitute into each eye 3 times per day for 6 months.
Study NCT05585554 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRIdian
Description: Stereotactic MRI-guided On-table Adaptive Radiation Therapy delivered on MRIdian linac
Study NCT05574907 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI PET/CT scan
Description: Patients with suspected breast cancer underwent 68Ga-FAPI PET/CT after an injection of 74-148 MBq (2-4 mCi) 68Ga-FAPI to image lesions of breast cancer.
Study NCT06301347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning through Play Plus
Description: Combination of two interventions: Learning through Play and Cognitive Behaviour Therapy
Study NCT06366503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractional Ablative CO2 Laser
Description: A fractional ablative DEKA SmartXide Tetra CO2 laser treatment was performed after a 14-day washout period. Subjects were numbed for 1 hour prior to procedure with topical numbing cream (lidocaine 23%, tetracaine 7%). The global face was treated with a single pass. Treatment parameters include power 20 W, spacing 500 um (13% density), Dwell time 1200 us DEKA pulse mode, spray mode on.
Study NCT06366503 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Ablative CO2 Laser
Description: A fractional ablative DEKA SmartXide Tetra CO2 laser treatment was performed after a 14-day washout period. Subjects were numbed for 1 hour prior to procedure with topical numbing cream (lidocaine 23%, tetracaine 7%). The global face was treated with a single pass. Treatment parameters include power 20 W, spacing 500 um (13% density), Dwell time 1200 us DEKA pulse mode, spray mode on.
Study NCT06366503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Cleanser
Description: Facial cleanser was to be used by subjects twice daily during the 14-day washout period and three times daily during the 14-day post-procedure timeline.
Study NCT06366503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial Cleanser
Description: Facial cleanser was to be used by subjects twice daily during the 14-day washout period and three times daily during the 14-day post-procedure timeline.
Study NCT06366503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Moisturizer
Description: A bland facial moisturizer was to be used by subjects twice daily during the 14-day washout period and three times daily between day 3 and 14 post-procedure. Two pumps were to be applied to the face (avoiding the upper eyelid) after applying the active and comparator.
Study NCT06366503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial Moisturizer
Description: A bland facial moisturizer was to be used by subjects twice daily during the 14-day washout period and three times daily between day 3 and 14 post-procedure. Two pumps were to be applied to the face (avoiding the upper eyelid) after applying the active and comparator.
Study NCT06366503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: During the 14-day washout period, a bland sunscreen was to be used by subjects in the morning after cleansing and facial moisturizer application with reapplications as needed throughout the day per FDA recommendations. For days 3-14 post-procedure, the bland sunscreen was to be used daily by subjects in the morning and afternoon after cleansing, split-face application of the active post-procedure cream and comparator anhydrous formulation, and facial moisturizer application.
Study NCT06366503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Description: During the 14-day washout period, a bland sunscreen was to be used by subjects in the morning after cleansing and facial moisturizer application with reapplications as needed throughout the day per FDA recommendations. For days 3-14 post-procedure, the bland sunscreen was to be used daily by subjects in the morning and afternoon after cleansing, split-face application of the active post-procedure cream and comparator anhydrous formulation, and facial moisturizer application.
Study NCT06366503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic Ointment
Description: The basic ointment was used only on the comparator side for three days (72 hours) post-procedure. This was a requirement of the comparator anhydrous formulation.
Study NCT04856397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Implant in Applicator
Description: Dexamethasone intravitreal implant
Study NCT04856397 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Eylea
Description: anti-VEGF medication
Study NCT04759846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib + Binimetinib
Description: The doses administered to patients with normal hepatic function will be the same as the recommended commercialised doses
Study NCT04759846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib + Binimetinib
Description: A smaller dose than the dose approved for patients with normal hepatic function has been defined
Study NCT04856397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eylea
Description: anti-VEGF medication
Study NCT04330378 — intervention group
Intervention type: OTHER
Intervention: Hospital-at-home
Description: As per experimental arm
Study NCT04330378 — intervention group
Intervention type: OTHER
Intervention: Usual in-hospital care
Description: As per control arm
Study NCT05029011 — intervention group
Intervention type: DEVICE
Intervention: BRAEBON VTS
Description: The BRAEBON VTS is a portable device that continuously monitors vital signs. Participants in the study will wear the BRAEBON VTS for 24 hours.
Study NCT05648396 — intervention group
Intervention type: OTHER
Intervention: FFRangio
Description: Assessing the physiologic significance of an intermediate coronary lesion/lesions using FFRangio - a non invasive method to calculate the fractional flow reserve (FFR) of the assessed lesion.
Study NCT06428864 — intervention group
Intervention type: DEVICE
Intervention: Plaster cast
Description: Wearing a Garchois brace produced after a plaster cast
Study NCT06428864 — intervention group
Intervention type: DEVICE
Intervention: 3D Scanning
Description: Wearing a Garchois brace produced after assessment of the thoracic volume with the 3D scan
Study NCT06475794 — intervention group
Intervention type: OTHER
Intervention: Patients with osteoporosis group
Description: Pain, Q angle, muscle strength and foot posture will be evaluated.
Study NCT06475794 — intervention group
Intervention type: OTHER
Intervention: Patients with osteoarthritis group
Description: Osteoarthritis patients will be evaluated in terms of pain, foot posture, Q angle and lower limbs muscle strength.
Study NCT06059729 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Al-Lisaan
Description: Al-Lisaan is a digital application for the self assessment and management of adult stutters.
Study NCT06059729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Al-Lisaan
Description: Al-Lisaan is a digital application for the self assessment and management of adult stutters.
Study NCT05739305 — intervention group
Intervention type: OTHER
Intervention: Risk factor
Description: No diagnostic or therapeutic intervention; the characteristics of subgroups will be analyzed by the cause of death certificated in the registry.
Study NCT05190471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
Description: Dose escalation of BP1002 monotherapy
Study NCT05190471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine (in combination with BP1002)
Description: Dose expansion of BP1002 in combination with decitabine
Study NCT05054465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: P.O 50mg QD Q28 days for 2 cycles pre-transplant Up to 50mg QD Q28 days maintnance post-transplant based on MTD
Study NCT05054465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: P.O 400mg QD Q28 days for 2 cycles pre-transplant Up to 400mg QD Q28 days maintnance post-transplant based on MTD
Study NCT05041725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Injection [Byfavo]
Description: Remimazolam injection and continuous infusion for postoperative sedation, 0.2 mg/kg for 1 min and continuous infusion of 1-2 mg/kg/hour
Study NCT05840900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Mindfulness Training
Description: Once daily, 5-10 minute mindfulness exercises for 8 week intervention period using the existing perinatal mindfulness application Expectful
Study NCT05225636 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thrombectomy
Description: Extraction of intracranial thrombus in an acute large vessel occlusion
Study NCT05130346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Description: Participants will be asked to attend group meetings for mindfulness training. Each meeting will last approximately one hour and will take place online via Zoom. The meetings will occur on a weekly basis, over an 8-week period.
Study NCT05086419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-symptom threshold aerobic exercise
Description: For the first three weeks, participants will be offered guided sub-symptom threshold aerobic exercise on a treadmill or exercise bike once a week. The remaining 2-4 sub-symptom threshold aerobic exercise workouts per. week will be on their own. Location and mode of exercise (treadmill, walking, jogging, exercise bike / bicycle, swimming, or elliptical machine) will be individually adapted to the patients experience, preferences and opportunities. The intensity of the sub-symptom threshold aerobic exercise will always be monitored using a heart rate monitor and/or ratings of perceived exertion (Borg RPE). If there still is a need for closer follow-up after the first three weeks, a physiotherapist in primary health care service will be involved under supervision from a physiotherapist (research fellow) in the project.
Study NCT04864717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline 100mg po once daily x 6 months
Description: active intervention
Study NCT04864717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin 40 mg po once daily x 6 months
Description: active intervention
Study NCT05268016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME3183
Description: ME3183 capsule
Study NCT06215417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotator cuff repair
Description: Arthroscopic rotator cuff repair augmented with graft.
Study NCT06215417 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repair
Description: Arthroscopic rotator cuff repair augmented with graft.
Study NCT06226662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM8074
Description: NM8074 will be administered as an intravenous infusion. In Cohort 1, all subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period.
Study NCT06226662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline Placebo will be administered as an intravenous infusion. In Cohort 2, all subjects will be administered saline placebo intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period.
Study NCT05268016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule